Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2019 | Updates from the ZUMA-8 trial: KTE-X19 for R/R CLL

Ian Flinn • 3 Jun 2019
ASCO 2019
Chronic Lymphocytic Leukemia Leukemia
ZUMA-8

Ian Flinn, MD, PhD, from Tennessee Oncology, Nashville, TN, discusses the ZUMA-8 trial (NCT03624036) looking at KTE-X19 for R/R chronic lymphocytic leukemia (CLL). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Ian Flinn

SGN35-027: Brentuximab vedotin with nivolumab, doxorubicin, and dacarbazine in HL 2:18
SGN35-027: Brentuximab vedotin with nivolumab, doxorubicin, and dacarbazine in HL
Ian Flinn • 9 Dec 2021
Unanswered questions in frontline CLL treatment 0:57
Unanswered questions in frontline CLL treatment
Ian Flinn • 9 Dec 2021
Umbralisib and ublituximab in patients with CLL and comorbidities 1:55
Umbralisib and ublituximab in patients with CLL and comorbidities
Ian Flinn • 9 Dec 2021
Debulking strategies in CLL before venetoclax therapy 2:48
Debulking strategies in CLL before venetoclax therapy
Ian Flinn • 9 Dec 2021

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals